Current Advance of Immune Evasion Mechanisms and Emerging Immunotherapies in Renal Cell Carcinoma

Yuli Jian; Kangkang Yang; Xiaoxin Sun; Jun Zhao; Kai Huang; Abdullah Aldanakh; Zhongyang Xu; Haotian Wu; Qiwei Xu; Lin Zhang; Chunyan Xu; Deyong Yang; Shujing Wang

doi:10.3389/fimmu.2021.639636

Frontiers in Immunology (Mar 2021)

Current Advance of Immune Evasion Mechanisms and Emerging Immunotherapies in Renal Cell Carcinoma

Yuli Jian,
Kangkang Yang,
Xiaoxin Sun,
Jun Zhao,
Kai Huang,
Abdullah Aldanakh,
Zhongyang Xu,
Haotian Wu,
Qiwei Xu,
Lin Zhang,
Chunyan Xu,
Deyong Yang,
Shujing Wang

Affiliations

Yuli Jian: Department of Biochemistry and Molecular Biology, Institute of Glycobiology, Dalian Medical University, Dalian, China
Kangkang Yang: Department of Biochemistry and Molecular Biology, Institute of Glycobiology, Dalian Medical University, Dalian, China
Xiaoxin Sun: Department of Biochemistry and Molecular Biology, Institute of Glycobiology, Dalian Medical University, Dalian, China
Jun Zhao: Department of Urology, First Affiliated Hospital of Dalian Medical University, Dalian, China
Kai Huang: Department of Urology, First Affiliated Hospital of Dalian Medical University, Dalian, China
Abdullah Aldanakh: Department of Urology, First Affiliated Hospital of Dalian Medical University, Dalian, China
Zhongyang Xu: Department of Biochemistry and Molecular Biology, Institute of Glycobiology, Dalian Medical University, Dalian, China
Haotian Wu: Department of Urology, First Affiliated Hospital of Dalian Medical University, Dalian, China
Qiwei Xu: Department of Biochemistry and Molecular Biology, Institute of Glycobiology, Dalian Medical University, Dalian, China
Lin Zhang: Department of Biochemistry and Molecular Biology, Institute of Glycobiology, Dalian Medical University, Dalian, China
Chunyan Xu: Department of Biochemistry and Molecular Biology, Institute of Glycobiology, Dalian Medical University, Dalian, China
Deyong Yang: Department of Urology, First Affiliated Hospital of Dalian Medical University, Dalian, China
Shujing Wang: Department of Biochemistry and Molecular Biology, Institute of Glycobiology, Dalian Medical University, Dalian, China

DOI: https://doi.org/10.3389/fimmu.2021.639636
Journal volume & issue: Vol. 12

Abstract

Read online

Renal cell carcinoma is a highly heterogeneous cancer group, and the complex microenvironment of the tumor provides appropriate immune evasion opportunities. The molecular mechanism of immune escape in renal cell carcinoma is currently a hot issue, focusing primarily on the major complex of histocompatibility, immunosuppressive cells, their secreted immunosuppressive cytokines, and apoptosis molecule signal transduction. Immunotherapy is the best treatment option for patients with metastatic or advanced renal cell carcinoma and combination immunotherapy based on a variety of principles has shown promising prospects. Comprehensive and in-depth knowledge of the molecular mechanism of immune escape in renal cell carcinoma is of vital importance for the clinical implementation of effective therapies. The goal of this review is to address research into the mechanisms of immune escape in renal cell carcinoma and the use of the latest immunotherapy. In addition, we are all looking forward to the latest frontiers of experimental combination immunotherapy.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords